1 BTC
=
- USD
Hologic Inc
As of May 30, 2026 at 24:05 UTC
Chart
About Hologic Inc
Hologic manufactures proprietary products for the healthcare needs of women. The company operates in four segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.
Market Statistics
Trading Metrics
How to Buy HOLX
Create Your Account
Sign up, deposit BTC, and transfer it to your Unified Trading Account. It only takes a moment.
Start Your Trade
From Terminal, click Trade Now on the asset you want to buy. You'll be purchasing its tokenized asset.
Buy HOLX
Enter the amount and confirm your purchase. That's it! You'll see the impact of the trade in your Unified Trading Account.
New to Tokenized Assets? Learn more in our Help Center.
Latest News
5 articlesHologic has completed its acquisition by Blackstone and TPG for approximately $18.3 billion. Shareholders receive $76 per share in cash plus a contingent value right (CVR) worth up to $3 per share tied to Breast Health business revenue milestones. The company has been delisted from Nasdaq, and José E. Almeida has been appointed as the new CEO.
The global molecular diagnostics market is projected to reach USD 33.51 billion by 2031, growing at a CAGR of 10.43% from 2026 to 2031. Growth is driven by increasing adoption of precision medicine, advancements in genomic testing technologies, and rising prevalence of infectious and chronic diseases. North America leads the market while Asia-Pacific is expected to be the fastest-growing region.
RadNet (NASDAQ: RDNT) reported record Q4 revenue of $547.7M (up 14.8% YoY) and adjusted EBITDA of $87.7M (up 16.9% YoY), beating analyst estimates. The company announced a $270M acquisition of Paris-based AI radiology firm Gleamer to strengthen its Digital Health division. RadNet guided for 2026 imaging center revenue growth of 17-19% and digital health revenue growth of 46-56%. Shares rose 7.45% in premarket trading.
The global scar treatment market is projected to grow from USD 26.60 billion in 2025 to USD 56.30 billion by 2033, with a CAGR of 9.91%. Growth is driven by increasing awareness of advanced cosmetic and reconstructive procedures, rising prevalence of acne, surgical, and traumatic scars, and technological advancements in minimally invasive treatments. The U.S. market alone is expected to reach USD 17.69 billion by 2033.
The global uterine fibroid market is projected to grow from USD 5.26 billion in 2025 to USD 9.43 billion by 2033 at a CAGR of 7.63%. Growth is driven by rising prevalence of fibroids (affecting 70-80% of women by age 50), technological advances in minimally invasive procedures with 60% adoption increase, and expanded healthcare infrastructure in emerging markets. Minimally invasive procedures and MRI-guided focused ultrasound are expected to see the fastest growth rates.
